Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Eileen W. Stalman"'
Autor:
Sofie Keijzer, Nienke Oskam, Pleuni Ooijevaar-de Heer, Maurice Steenhuis, Jim B.D. Keijser, Luuk Wieske, Koos P.J. van Dam, Eileen W. Stalman, Laura Y.L. Kummer, Laura Boekel, Taco W. Kuijpers, Anja ten Brinke, S. Marieke van Ham, Filip Eftimov, Sander W. Tas, Gerrit J. Wolbink, Theo Rispens
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundRheumatoid factors (RFs) are autoantibodies that target the Fc region of IgG, and are found in patients with rheumatic diseases as well as in the healthy population. Many studies suggest that an immune trigger may (transiently) elicit RF re
Externí odkaz:
https://doaj.org/article/f23a6c0fb19b45e796cbf67b6dbbd340
Autor:
Koos P. J. van Dam, Adriaan G. Volkers, Luuk Wieske, Eileen W. Stalman, Laura Y. L. Kummer, Zoé L. E. van Kempen, Joep Killestein, Sander W. Tas, Laura Boekel, Gerrit J. Wolbink, Anneke J. van der Kooi, Joost Raaphorst, R. Bart Takkenberg, Geert R. A. M. D’Haens, Phyllis I. Spuls, Marcel W. Bekkenk, Annelie H. Musters, Nicoline F. Post, Angela L. Bosma, Marc L. Hilhorst, Yosta Vegting, Frederike J. Bemelman, Alexandre E. Voskuyl, Bo Broens, Agner Parra Sanchez, Cécile A. C. M. van Els, Jelle de Wit, Abraham Rutgers, Karina de Leeuw, Barbara Horváth, Jan J. G. M. Verschuuren, Annabel M. Ruiter, Lotte van Ouwerkerk, Diane van der Woude, Renée C. F. Allaart, Y. K. Onno Teng, Pieter van Paassen, Matthias H. Busch, Papay B. P. Jallah, Esther Brusse, Pieter A. van Doorn, Adája E. Baars, Dirk Jan Hijnen, Corine R. G. Schreurs, W. Ludo van der Pol, H. Stephan Goedee, Maurice Steenhuis, Sofie Keijzer, Jim B. D. Keijser, Olvi Cristianawati, Anja ten Brinke, Niels J. M. Verstegen, S. Marieke van Ham, Theo Rispens, Taco W. Kuijpers, Mark Löwenberg, Filip Eftimov, on behalf of the T2B! Immunity against SARS-CoV-2 study group
Publikováno v:
BMC Infectious Diseases, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressants (ISPs) may have impaired long-term humoral immune responses and increased disease activity after SARS-CoV-2 infection. We aimed to investigate long-
Externí odkaz:
https://doaj.org/article/8a6e2bdaa5404154a54ecf8fcb54843c
Autor:
Luuk Wieske, Laura Y. L. Kummer, Koos P. J. van Dam, Eileen W. Stalman, Anneke J. van der Kooi, Joost Raaphorst, Mark Löwenberg, R. Bart Takkenberg, Adriaan G. Volkers, Geert R. A. M. D’Haens, Sander W. Tas, Phyllis I. Spuls, Marcel W. Bekkenk, Annelie H. Musters, Nicoline F. Post, Angela L. Bosma, Marc L. Hilhorst, Yosta Vegting, Frederike J. Bemelman, Joep Killestein, Zoé L. E. van Kempen, Alexandre E. Voskuyl, Bo Broens, Agner Parra Sanchez, Gertjan Wolbink, Laura Boekel, Abraham Rutgers, Karina de Leeuw, Barbara Horváth, Jan J. G. M. Verschuuren, Annabel M. Ruiter, Lotte van Ouwerkerk, Diane van der Woude, Cornelia F. Allaart, Y. K. Onno Teng, Pieter van Paassen, Matthias H. Busch, B. Papay Jallah, Esther Brusse, Pieter A. van Doorn, Adája E. Baars, Dirkjan Hijnen, Corine R. G. Schreurs, W. Ludo van der Pol, H. Stephan Goedee, Maurice Steenhuis, Theo Rispens, Anja ten Brinke, Niels J. M. Verstegen, Koos A. H. Zwinderman, S. Marieke van Ham, Taco W. Kuijpers, Filip Eftimov, on behalf of the T2B! immunity against SARS-CoV-2 study group
Publikováno v:
BMC Medicine, Vol 20, Iss 1, Pp 1-6 (2022)
Abstract Background Studies have suggested incremental short-term adverse events (AE) after repeated vaccination. In this report, we assessed occurrence and risk factors for short-term AEs following repeated SARS-CoV-2 vaccination in patients with va
Externí odkaz:
https://doaj.org/article/67db8621c3964b7a9443d09b66e09e5f
Autor:
Koos P. J. van Dam, Laura Hogenboom, Eileen W. Stalman, Laura Y. L. Kummer, Maurice Steenhuis, Jim B. D. Keijser, Anja ten Brinke, S. Marieke van Ham, Taco W. Kuijpers, Theo Rispens, Luuk Wieske, Filip Eftimov, Eva M. Strijbis, Joep Killestein, Zoé L. E. van Kempen
Publikováno v:
Frontiers in Neurology, Vol 13 (2022)
IntroductionDuring the COVID-19 pandemic, certain disease modifying therapies (DMTs) used in multiple sclerosis (MS), such as anti-CD20 therapies, have been associated with decreased humoral responses after SARS-CoV-2 vaccination. Hybrid immunity, re
Externí odkaz:
https://doaj.org/article/0b276eefa8dc4d3eaf40db874279d0cb
Autor:
Niels JM Verstegen, Ruth R Hagen, Jet van den Dijssel, Lisan H Kuijper, Christine Kreher, Thomas Ashhurst, Laura YL Kummer, Maurice Steenhuis, Mariel Duurland, Rivka de Jongh, Nina de Jong, C Ellen van der Schoot, Amélie V Bos, Erik Mul, Katherine Kedzierska, Koos PJ van Dam, Eileen W Stalman, Laura Boekel, Gertjan Wolbink, Sander W Tas, Joep Killestein, Zoé LE van Kempen, Luuk Wieske, Taco W Kuijpers, Filip Eftimov, Theo Rispens, S Marieke van Ham, Anja ten Brinke, Carolien E van de Sandt, On behalf of the T2B! immunity against SARS-CoV-2 study group
Publikováno v:
eLife, Vol 11 (2022)
Background: Patients affected by different types of autoimmune diseases, including common conditions such as multiple sclerosis (MS) and rheumatoid arthritis (RA), are often treated with immunosuppressants to suppress disease activity. It is not full
Externí odkaz:
https://doaj.org/article/731224c95d814455a088b97c4f3d1a9f
Autor:
Ronald F van Vollenhoven, Sander W Tas, Taco W Kuijpers, Maarten Boers, Michael T Nurmohamed, Gertjan Wolbink, Irene E van der Horst-Bruinsma, Theo Rispens, Willem Lems, Alexandre Voskuyl, Carla A Wijbrandts, S Marieke van Ham, Martijn Gerritsen, Erik H Vogelzang, Luuk Wieske, Laura Boekel, Femke Hooijberg, Yaëlle R Besten, Maureen Leeuw, Sadaf Atiqi, C Krieckaert, Bas Dijkshoorn, Siham Bakhlakh, Juliette J Crooijmans, Filip Eftimov, Laura Y Kummer, PJ Koos van Dam, Eileen W Stalman, Maurice Steenhuis, Sofie Keijzer, Olvi Cristianawati, Jim Keijser, Floris C Loeff
Publikováno v:
RMD Open, Vol 8, Iss 1 (2022)
Externí odkaz:
https://doaj.org/article/c31dbe2993a2456ab42dc303970a81d9
Autor:
Laura Boekel, Yaëlle R Besten, Femke Hooijberg, Rosa Wartena, Maurice Steenhuis, Erik Vogelzang, Maureen Leeuw, Sadaf Atiqi, Sander W Tas, Willem F Lems, S Marieke van Ham, Filip Eftimov, Eileen W Stalman, Luuk Wieske, Taco W Kuijpers, Alexandre E Voskuyl, Ronald F van Vollenhoven, Martijn Gerritsen, Charlotte Krieckaert, Theo Rispens, Maarten Boers, Mike T Nurmohamed, Gertjan Wolbink
Publikováno v:
The Lancet Rheumatology, 4(11), e747-e750. Lancet Publishing Group
Boekel, L, Besten, Y R, Hooijberg, F, Wartena, R, Steenhuis, M, Vogelzang, E, Leeuw, M, Atiqi, S, Tas, S W, Lems, W F, van Ham, S M, Eftimov, F, Stalman, E W, Wieske, L, Kuijpers, T W, Voskuyl, A E, van Vollenhoven, R F, Gerritsen, M, Krieckaert, C, Rispens, T, Boers, M, Nurmohamed, M T & Wolbink, G 2022, ' SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period ', The Lancet Rheumatology, vol. 4, no. 11, pp. e747-e750 . https://doi.org/10.1016/S2665-9913(22)00221-1
The Lancet. Rheumatology, 4(11), e747-e750
Boekel, L, Besten, Y R, Hooijberg, F, Wartena, R, Steenhuis, M, Vogelzang, E, Leeuw, M, Atiqi, S, Tas, S W, Lems, W F, van Ham, S M, Eftimov, F, Stalman, E W, Wieske, L, Kuijpers, T W, Voskuyl, A E, van Vollenhoven, R F, Gerritsen, M, Krieckaert, C, Rispens, T, Boers, M, Nurmohamed, M T & Wolbink, G 2022, ' SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period ', The Lancet Rheumatology, vol. 4, no. 11, pp. e747-e750 . https://doi.org/10.1016/S2665-9913(22)00221-1
The Lancet. Rheumatology, 4(11), e747-e750
Autor:
Laura Boekel, Eileen W Stalman, Luuk Wieske, Femke Hooijberg, Koos P J van Dam, Yaëlle R Besten, Laura Y L Kummer, Maurice Steenhuis, Zoé L E van Kempen, Joep Killestein, Adriaan G Volkers, Sander W Tas, Anneke J van der Kooi, Joost Raaphorst, Mark Löwenberg, R Bart Takkenberg, Geert R A M D'Haens, Phyllis I Spuls, Marcel W Bekkenk, Annelie H Musters, Nicoline F Post, Angela L Bosma, Marc L Hilhorst, Yosta Vegting, Frederike J Bemelman, Alexandre E Voskuyl, Bo Broens, Agner Parra Sanchez, Cécile A C M van Els, Jelle de Wit, Abraham Rutgers, Karina de Leeuw, Barbara Horváth, Jan J G M Verschuuren, Annabel M Ruiter, Lotte van Ouwerkerk, Diane van der Woude, Cornelia F Allaart, Y K Onno Teng, Pieter van Paassen, Matthias H Busch, Papay B P Jallah, Esther Brusse, Pieter A van Doorn, Adája E Baars, Dirk Jan Hijnen, Corine R G Schreurs, W Ludo van der Pol, H Stephan Goedee, Erik H Vogelzang, Maureen Leeuw, Sadaf Atiqi, Ronald van Vollenhoven, Martijn Gerritsen, Irene E van der Horst-Bruinsma, Willem F Lems, Mike T Nurmohamed, Maarten Boers, Sofie Keijzer, Jim Keijser, Carolien van de Sandt, Arend Boogaard, Olvi Cristianawati, Anja ten Brinke, Niels J M Verstegen, Koos A H Zwinderman, S Marieke van Ham, Theo Rispens, Taco W Kuijpers, Gertjan Wolbink, Filip Eftimov, Rivka de Jongh, Lisan Kuijper, Mariel Duurland, Ruth Hagen, Jet van den Dijssel, Christine Kreher, Amelie Bos, Viriginia Palomares Cabeza, Veronique Konijn, George Elias, Juan Vallejo, Marrit van Gils, Tom Ashhurst, Sergey Nejentsev, Elham Mirfazeli
Publikováno v:
The Lancet Rheumatology, 4(6), e417-e429. Lancet Publishing Group
The Lancet. Rheumatology, 4, e417-e429
T2B! immunity against SARS-CoV-2 study group 2022, ' Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants : a substudy of two prospective cohort studies ', The Lancet Rheumatology, vol. 4, no. 6, pp. e417-e429 . https://doi.org/10.1016/S2665-9913(22)00102-3
The Lancet Rheumatology, 4(6), E417-E429. ELSEVIER
The Lancet. Rheumatology, 4, 6, pp. e417-e429
The Lancet. Rheumatology, 4(6), e417-e429. Elsevier Ltd
The Lancet Rheumatology, 4(6), e417-e429. Elsevier
The Lancet. Rheumatology, 4, e417-e429
T2B! immunity against SARS-CoV-2 study group 2022, ' Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants : a substudy of two prospective cohort studies ', The Lancet Rheumatology, vol. 4, no. 6, pp. e417-e429 . https://doi.org/10.1016/S2665-9913(22)00102-3
The Lancet Rheumatology, 4(6), E417-E429. ELSEVIER
The Lancet. Rheumatology, 4, 6, pp. e417-e429
The Lancet. Rheumatology, 4(6), e417-e429. Elsevier Ltd
The Lancet Rheumatology, 4(6), e417-e429. Elsevier
Contains fulltext : 251784.pdf (Publisher’s version ) (Closed access) BACKGROUND: Concerns have been raised regarding the risks of SARS-CoV-2 breakthrough infections in vaccinated patients with immune-mediated inflammatory diseases treated with imm
Autor:
Laura Y Kummer, Sofie Keijzer, Erik H Vogelzang, Gertjan Wolbink, Laura Boekel, Luuk Wieske, Filip Eftimov, Maurice Steenhuis, Michael T Nurmohamed, Ronald van Vollenhoven, Gestur Vidarsson, T. Rispens, Koos P J van Dam, Joep Killestein, Olvi Cristianawati, S. Marieke van Ham, Zoé L.E. van Kempen, Yaëlle R Besten, Eileen W Stalman, Sander W. Tas, Alexandre E Voskuyl, Taco W. Kuijpers, Femke Hooijberg, Maarten Boers
Publikováno v:
Boekel, L, Steenhuis, M, Hooijberg, F, Besten, Y R, van Kempen, Z L E, Kummer, L Y, van Dam, K P J, Stalman, E W, Vogelzang, E H, Cristianawati, O, Keijzer, S, Vidarsson, G, Voskuyl, A E, Wieske, L, Eftimov, F, van Vollenhoven, R, Kuijpers, T W, van Ham, S M, Tas, S W, Killestein, J, Boers, M, Nurmohamed, M T, Rispens, T & Wolbink, G 2021, ' Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands : a substudy of data from two prospective cohort studies ', The Lancet Rheumatology, vol. 3, no. 11, pp. e778-e788 . https://doi.org/10.1016/S2665-9913(21)00222-8, https://doi.org/10.1016/S2665-9913(21)00222-8
The Lancet. Rheumatology, 3(11), e778-e788. Elsevier Ltd
The Lancet. Rheumatology
The Lancet Rheumatology, 3(11), e778-e788. Lancet Publishing Group
The Lancet. Rheumatology, 3(11), e778-e788. Elsevier Ltd
The Lancet. Rheumatology
The Lancet Rheumatology, 3(11), e778-e788. Lancet Publishing Group
Background: Data are scarce on immunogenicity of COVID-19 vaccines in patients with autoimmune diseases, who are often treated with immunosuppressive drugs. We aimed to investigate the effect of different immunosuppressive drugs on antibody developme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5058ec41cc875d2674bd64b83a76a66b
https://dare.uva.nl/personal/pure/en/publications/antibody-development-after-covid19-vaccination-in-patients-with-autoimmune-diseases-in-the-netherlands(036a10d7-30ae-4847-93fc-d95a956d1c63).html
https://dare.uva.nl/personal/pure/en/publications/antibody-development-after-covid19-vaccination-in-patients-with-autoimmune-diseases-in-the-netherlands(036a10d7-30ae-4847-93fc-d95a956d1c63).html
Autor:
Virginia Palomares Cabeza, Laura Y.L. Kummer, Luuk Wieske, Ruth R. Hagen, Mariel Duurland, Veronique A.L. Konijn, Koos P.J. van Dam, Eileen W. Stalman, Carolien E. van de Sandt, Laura Boekel, Niels J.M. Verstegen, Maurice Steenhuis, Theo Rispens, Sander W. Tas, Gertjan Wolbink, Joep Killestein, Taco W. Kuijpers, S. Marieke van Ham, Filip Eftimov, Anja ten Brinke, Zoé L.E. van Kempen
Publikováno v:
Neurol Neuroimmunol Neuroinflamm
Neurology(R) neuroimmunology & neuroinflammation, 9(4). Lippincott Williams and Wilkins
Target-to-B! (T2B!) SARS-CoV-2 study group 2022, ' Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod ', Neurology(R) neuroimmunology & neuroinflammation, vol. 9, no. 4 . https://doi.org/10.1212/NXI.0000000000001178
Neurology® Neuroimmunology & Neuroinflammation, 9(4):e1178. Lippincott Williams & Wilkins
Neurology® neuroimmunology & neuroinflammation, 9(4). Lippincott Williams and Wilkins
Neurology(R) neuroimmunology & neuroinflammation, 9(4). Lippincott Williams and Wilkins
Target-to-B! (T2B!) SARS-CoV-2 study group 2022, ' Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod ', Neurology(R) neuroimmunology & neuroinflammation, vol. 9, no. 4 . https://doi.org/10.1212/NXI.0000000000001178
Neurology® Neuroimmunology & Neuroinflammation, 9(4):e1178. Lippincott Williams & Wilkins
Neurology® neuroimmunology & neuroinflammation, 9(4). Lippincott Williams and Wilkins
ObjectivesTo evaluate whether a third vaccination shows an added effect on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) T-cell responses in patients with multiple sclerosis treated with ocrelizumab or fingolimod.MethodsThis is a subst